Abstract
Activated Cdc42-associated kinase 1 (ACK1), a kind of tyrosine kinase, is considered to be an oncogene in many cancers, and it is likely to become a potential target for cancer treatment. We found that the expression of the ACK1 gene in colon cancer was higher than that in normal tissues adjacent to cancer, and high expression of the ACK1 gene was associated with poor prognosis of patients. We assessed the prognosis of colon cancer based on ACK1-related genes and constructed a model that can predict the prognosis of colon cancer patients in colon cancer data from The Cancer Genome Atlas (TCGA) database. We then explored the relationship between ACK1 and the immune microenvironment of colon cancer. The overexpression of ACK1 might hinder the function of antigen-presenting cells. The colon cancer prognosis prediction model we constructed has certain significance for clinicians to judge the prognosis of patients with colon cancer. The expression of the ACK1 gene might affect the infiltration level of a variety of immune cells and immunomodulators in the immune microenvironment.
Highlights
Colon cancer is a major health burden worldwide, and the incidence of colon cancer is on the rise [5]
associated kinase 1 (ACK1)/TNK2 is differentially expressed in colon cancer and adjacent tissues We adopted colon cancer data from the The Cancer Genome Atlas (TCGA) database
Through the analysis of immune infiltration, we found that the ACK1 gene is related to a variety of immune cells, indicating that ACK1 may be involved in the regulation of the tumour immune microenvironment, which plays a very complicated and unclear role
Summary
Colon cancer is a major health burden worldwide, and the incidence of colon cancer is on the rise [5]. With in-depth research on the mechanism of colon cancer occurrence and development in recent years, many new treatment methods have been discovered, including molecular targeted therapy and immunotherapy, but these treatment methods have limited efficacy. The gene targets of precision therapy drugs mainly included MSI [30], BRAF [1], KRAS [7], NRAS [21], HER2 [10], NTRK [23], etc. These findings still cannot meet the needs of the many colon cancer patients with different molecular types. More effective therapeutic targets and more precise molecular classification of colon cancer need to be explored
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
